Guidelines published by the American Society of Clinical Oncology address management of immune-related adverse events in patients treated with immune checkpoint inhibitors, including autoimmune diabetes resulting from pembrolizumab toxicity. The guidelines emphasize early recognition of abrupt insulin deficiency and diabetic ketoacidosis (DKA), but do not specifically note any evidence of preventive medications. The discussed management recommendations largely reflect expert consensus. Patients developing new cases of polyuria, polydipsia, weight loss, or lethargy should undergo prompt assessment of glucose, electrolytes, anion gap, ketones, and acid-base status, with C-peptide, insulin, and pancreatic autoantibodies obtained to support diagnosis without delaying treatment. When autoimmune diabetes is suspected, insulin initiation and urgent endocrinology consultation are recommended, with hospitalization appropriate if timely outpatient management is unavailable, even without established DKA. For grade 2 toxicity, including autoimmune diabetes without ketoacidosis, immunotherapy may be withheld until glucose is controlled, whereas grade 3-4 toxicity requires treatment interruption until improvement to grade 1 or less and inpatient management when DKA is present. Because long-acting insulin alone cannot adequately replace lost pancreatic function, the suggested starting total daily insulin requirement is 0.3-0.4 units/kg/day. Immunosuppression is not indicated, while permanent immunotherapy discontinuation is generally unnecessary when endocrine dysfunction is controlled with replacement therapy. [1]
A comprehensive 2025 consensus paper discusses several guidelines, including the American Society of Clinical Oncology, Society for Immunotherapy of Cancer, and European Society for Medical Oncology. While not specific to pembrolizumab only, checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM) occurs in approximately 0.4%-1.9% of ICI-treated patients and is associated almost exclusively with anti-PD-1/anti-PD-L1 therapy, with greater risk when these agents are combined with anti-CTLA-4 therapy. Median onset is approximately 12 weeks after treatment initiation, although cases occurring years after initiation demonstrate that risk persists beyond the early treatment period. Presentation is frequently abrupt, with diabetic ketoacidosis (DKA) present in 45%-67% of cases at diagnosis. These estimates should be distinguished from the substantially higher frequency of hyperglycemia from all causes during ICI therapy, which includes corticosteroid effects and pre-existing type 2 diabetes. [2]
Diagnosis of CIADM requires new-onset hyperglycemia, defined as glucose ≥11.1 mmol/L (approximately 200 mg/dL) and/or HbA1c ≥6.5%, together with a low C-peptide concentration of <0.4 nmol/L within one month of presentation. Distinguishing autoimmune insulin deficiency from steroid-induced hyperglycemia and pancreatitis-associated diabetes is essential because their treatment requirements differ.The consensus does not identify a pharmacologic intervention proven to prevent CIADM. For patients starting an ICI without additional hyperglycemia risk factors, glucose testing is recommended with each treatment cycle, together with HbA1c every three months. Patients commencing corticosteroids or developing elevated lipase warrant closer monitoring, preferably including postprandial glucose because fasting measurements may underestimate steroid-related hyperglycemia. Monitoring is recommended within two weeks of starting corticosteroids, after dose increases, and at least every four weeks thereafter until corticosteroids are discontinued or hyperglycemia resolves following dose reduction. Patients with pre-existing type 2 diabetes, newly detected hyperglycemia, or elevated HbA1c should receive a glucose meter and education regarding self-monitoring and warning symptoms, with at least daily testing when glucose remains >10 mmol/L. Surveillance should continue throughout ICI treatment and for 12 months after completion, followed by routine long-term diabetes screening. [2]
Because DKA is common at presentation, all patients with suspected CIADM should undergo capillary ketone testing; elevated ketones or an otherwise unexplained serum bicarbonate <16 mmol/L warrant hospital assessment for possible DKA. The broader assessment algorithm recommends ketone measurement when glucose exceeds 15 mmol/L, or exceeds 10 mmol/L in patients taking an SGLT2 inhibitor. Glucose >15 mmol/L together with ketones >2 mmol/L warrants direct emergency assessment. DKA treatment requires insulin infusion, fluid and electrolyte replacement, and close metabolic monitoring, frequently in an intensive care setting. Patients receiving SGLT2 inhibitors also require education regarding euglycemic DKA and the ability to monitor ketones; if this is impractical, discontinuation of the SGLT2 inhibitor should be considered. [2]
Established CIADM requires lifelong insulin because follow-up findings demonstrate persistent, profound loss of beta-cell function. The proposed initial subcutaneous regimen is once-daily long-acting insulin plus rapid-acting insulin with each of three daily meals. Endocrinology involvement is recommended for initial stabilization, education, and ongoing adjustment, particularly because minimal residual insulin secretion can produce substantial glycemic variability. A general glucose target of 5-10 mmol/L is suggested, with more flexible targets for older or palliative patients and those experiencing frequent unpredictable hypoglycemia. Continuous glucose monitoring and insulin pump therapy should be considered, alongside education about hypoglycemia, sick-day insulin management, ketone monitoring, and DKA. Patients with malabsorptive symptoms should also be assessed for concurrent pancreatic exocrine insufficiency, with pancreatic enzyme replacement considered when fecal elastase is low. Regarding continuation of pembrolizumab or another ICI, the oncology guidelines summarized in the paper recommend withholding treatment during DKA or severe metabolic instability until the acute complication has resolved or the patient is stable; moderate hyperglycemia may also warrant temporary interruption. [2]
A 2026 systematic review and meta-analysis synthesized data from 31 randomized controlled trials (N= 15,417 participants) to evaluate islet function impairment (IFI) outcomes associated with immune checkpoint inhibitors (ICPis) in cancer patients. The majority of trials involved patients with non-small cell lung cancer (NSCLC; n= 8 studies), followed by gastric and/or gastroesophageal cancer (n= 4 studies), melanoma and ovarian cancer (n= 3 each). Treatment regimens compared with either chemoradiotherapy or placebo included pembrolizumab (15), durvalumab (4), nivolumab (3), atezolizumab and avelumab (2 each), and tislelizumab, sugemalimab, cemiplimab, serplulimab, and toripalimab (1 each). The primary outcome was the incidence of IFI which included hyperglycemia, diabetes mellitus (DM), diabetic ketoacidosis( DKA), and type 1 diabetes mellitus (T1DM), with subgroup analyses by ICPi class, individual agent, cancer type, and treatment modality. Overall, ICPis significantly increased the risk of IFI of any grade compared with non-ICPi regimens (risk ratio [RR] 1.30; 95% CI, 1.10–1.53; p= 0.002). ICPi use was also associated with an increased risk of T1DM (RR 3.38; 95% CI, 1.66–6.88; p= 0.0008). Subgroup analyses found significantly increased IFI risk with PD-1 inhibitors (RR 1.53; 95% CI, 1.21–1.93; p= 0.0004), particularly pembrolizumab ((RR 2.38; 95% CI, 1.43–3.97; p= 0.0009) and with NSCLC patients (RR 1.32; 95% CI, 1.01–1.72; p= 0.04). ICPi monotherapy was associated with a significantly higher risk of any-grade and severe IFI (RR 1.43 and 3.39, respectively) than ICPi plus chemotherapy (RR 1.23 and 1.53, respectively). Risk of bias assessments and sensitivity analyses supported the reliability of the findings. The authors emphasized the importance of multidisciplinary monitoring and proactive blood glucose control to facilitate early identification and management of ICPi-associated endocrine complications. [3]
A 2026 network meta-analysis evaluated the comparative risk of endocrine adverse events associated with immune checkpoint inhibitor (ICI)-based regimens versus conventional therapies in patients with colorectal cancer (CRC). The analysis included 6 randomized controlled trials (N= 1,648 patients) and assessed several ICI-based strategies, including pembrolizumab and avelumab monotherapy, ICI combinations with tyrosine kinase inhibitors (TKIs), and ICI combinations with chemotherapy and anti-angiogenic antibodies. Endocrine adverse events evaluated included hypothyroidism, hyperthyroidism, thyroiditis, adrenal insufficiency, and diabetes mellitus, with outcomes stratified by severity (all-grade and grade 3–4). [4]
All ICI-containing regimens were associated with an increased risk of endocrine adverse events compared with conventional therapy, with differences across treatment strategies. Pembrolizumab monotherapy and ICI plus TKI regimens were associated with increased hypothyroidism risk (RR 4.44 and 5.62, respectively). Hyperthyroidism risk was significantly elevated with ICI plus TKI and ICI plus chemotherapy and anti-angiogenic antibody combinations. Although thyroiditis, diabetes mellitus, and adrenal insufficiency showed trends toward increased risk, wide confidence intervals limited definitive conclusions. Grade 1–2 events accounted for most of the endocrine toxicity burden, whereas grade 3–4 events were uncommon and estimates were limited by low statistical power. SUCRA rankings identified conventional therapy as having the lowest endocrine toxicity risk, followed by ICI plus chemotherapy and anti-angiogenic antibodies, ICI plus TKI, pembrolizumab, and avelumab regimens. Risk-of-bias assessments indicated moderate methodological quality, with no high-risk domains identified. Overall, ICI-based regimens were associated with increased endocrine toxicity in patients with CRC, predominantly low-grade thyroid dysfunction. These findings support routine endocrine monitoring, particularly thyroid function assessment, during ICI therapy, with attention to differences in toxicity risk across treatment regimens. [4]
Additional meta-analyses have demonstrated increased risks of endocrine-related adverse events associated with ICI-containing regimens, with toxicity profiles varying by drug class and treatment combination. One meta-analysis found that CTLA-4 blockade, particularly ipilimumab, was associated with a higher incidence of hypophysitis (5.6%) compared with nivolumab (0.5%) and pembrolizumab (1.1%), increasing to 10.5% with combined CTLA-4 and PD-1 inhibition. Conversely, thyroid dysfunction was more frequently associated with PD-1/PD-L1 inhibitors. Hypothyroidism incidence ranged from 3.8% with ipilimumab to 8.5% with pembrolizumab, increasing to 15.1% with certain combination regimens. Hypothyroidism risk was significantly elevated across ICIs compared with placebo or chemotherapy (e.g., nivolumab RR 11.19; 95% CI, 4.31–29.08; p <0.001). Diabetes mellitus was less common and primarily associated with PD-1/PD-L1 inhibitors, with reported incidences of 2.0% with nivolumab, 2.0% with pembrolizumab plus ipilimumab, and 0.4% with pembrolizumab monotherapy. [5]
A separate meta-analysis evaluating enfortumab vedotin (EV), alone or combined with pembrolizumab, in patients with advanced urothelial carcinoma found that hyperglycemia occurred in 10.3% of patients (95% CI, 8.6–12.2%), including high-grade events in 5.7% (95% CI, 4.5–7.1%). Compared with control regimens, EV was associated with significantly increased risks of all-grade (RR 16.97; 95% CI, 6.22–48.25) and high-grade hyperglycemia (RR 34.78; 95% CI, 4.77–253.43; both p <0.001). However, hyperglycemia incidence did not significantly differ between EV monotherapy and EV plus pembrolizumab (9.0% vs. 11.5%; p= 0.16), suggesting that adding pembrolizumab did not further increase the hyperglycemia risk associated with EV. The authors noted that inconsistent reporting of corticosteroid use limited assessment of its potential contribution to hyperglycemia risk and highlighted the need for prospective studies to better characterize the risk of hyperglycemia associated with ICI-containing regimens. [6]